Bladder Cancer

As leaders in the development of the most sophisticated treatments for people with bladder cancer, we have one of the largest bladder cancer clinical trials programs in the United States. A team of urologic surgeons, medical oncologists, imaging specialists, and urologic pathologists collaborates to diagnose and treat people with bladder cancer.

Our research studies give you access to the newest approaches to care, including the latest diagnostic imaging techniques, such as PET/MRI scans, and advanced treatments, including immunotherapy, robotic-assisted surgery, and blue light cystoscopy to detect and remove early stage bladder cancer.

Clinical Trials and Research Studies

Phase 2

A Phase II Open Label Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1 / PD-L1 Based Immunotherapy

Learn More

Phase 1

A PHASE 1B OPEN-LABEL MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR 214 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER OR METASTATIC NON-S ALL CELL LUNG CANCER

Learn More

Phase 1

Phase 1b Open-label Study of MK-7162 in Combination with Pembrolizumab (MK-3475) +/- other therapies in Participants with Advanced Solid Tumors

Learn More

Phase 1

A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Learn More